István Láng

9.0k total citations · 1 hit paper
118 papers, 4.4k citations indexed

About

István Láng is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, István Láng has authored 118 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 23 papers in Molecular Biology. Recurrent topics in István Láng's work include Advanced Breast Cancer Therapies (27 papers), HER2/EGFR in Cancer Research (22 papers) and Breast Cancer Treatment Studies (17 papers). István Láng is often cited by papers focused on Advanced Breast Cancer Therapies (27 papers), HER2/EGFR in Cancer Research (22 papers) and Breast Cancer Treatment Studies (17 papers). István Láng collaborates with scholars based in Hungary, United States and Belgium. István Láng's co-authors include John Crown, Sophia Randolph, Katalin Boér, Richard S. Finn, Dennis J. Slamon, Xin Huang, Tamás Pintér, Igor Bondarenko, Marcus Schmidt and Sindy T. Kim and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

István Láng

111 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

2014 1.4k citations Richard S. Finn, John Crown et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
István Láng Hungary	26	2.7k	2.2k	1.2k	717	543	118	4.4k
Florence Dalenc France	33	2.6k 1.0×	1.6k 0.7×	1.3k 1.1×	1.3k 1.9×	385 0.7×	209	4.5k
Tsunehiro Oyama Japan	40	2.8k 1.0×	1.6k 0.7×	1.3k 1.0×	2.6k 3.7×	296 0.5×	136	6.7k
Yen‐Shen Lu Taiwan	36	3.3k 1.2×	2.6k 1.2×	2.1k 1.7×	2.3k 3.2×	570 1.0×	238	6.5k
Margaretha Rudas Austria	41	2.4k 0.9×	984 0.4×	2.1k 1.7×	883 1.2×	632 1.2×	129	4.7k
Markus Borner Switzerland	43	3.0k 1.1×	1.8k 0.8×	847 0.7×	1.8k 2.5×	169 0.3×	126	5.6k
D C Tormey United States	32	2.1k 0.8×	718 0.3×	1.1k 0.9×	561 0.8×	644 1.2×	55	3.6k
Andries M. Bergman Netherlands	33	1.8k 0.7×	1.6k 0.7×	797 0.6×	1.6k 2.3×	219 0.4×	158	4.5k
Evangelos Briasoulis Greece	37	2.5k 1.0×	905 0.4×	855 0.7×	1.5k 2.0×	214 0.4×	151	4.8k
Shigehira Saji Japan	39	3.9k 1.5×	1.3k 0.6×	1.8k 1.4×	2.3k 3.2×	2.3k 4.2×	252	7.2k
Lin Wu China	34	2.6k 1.0×	2.1k 0.9×	1.3k 1.1×	1.4k 2.0×	94 0.2×	231	5.1k

Countries citing papers authored by István Láng

Since Specialization

Citations

This map shows the geographic impact of István Láng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by István Láng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites István Láng more than expected).

Fields of papers citing papers by István Láng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by István Láng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by István Láng. The network helps show where István Láng may publish in the future.

Co-authorship network of co-authors of István Láng

This figure shows the co-authorship network connecting the top 25 collaborators of István Láng. A scholar is included among the top collaborators of István Láng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with István Láng. István Láng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rohrberg, Kristoffer Staal, Zsuzsanna Pápai, Rikke Løvendahl Eefsen, et al.. (2024). 19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab.. Journal of Clinical Oncology. 42(16_suppl). 2641–2641. 1 indexed citations

Chic, Núria, Stephen J. Luen, Paolo Nucíforo, et al.. (2021). Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer. JNCI Journal of the National Cancer Institute. 114(3). 467–470. 10 indexed citations

Leone, José Pablo, Bernard F. Cole, Meredith M. Regan, et al.. (2020). Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial. Cancer. 127(5). 700–708. 5 indexed citations

Láng, István, et al.. (2020). Potential Drug–Drug Interactions with Combination Volasertib + Itraconazole: A Phase I, Fixed-sequence Study in Patients with Solid Tumors. Clinical Therapeutics. 42(11). 2214–2224. 7 indexed citations

Eiger, Daniel, Noam Pondé, Dominique Agbor‐Tarh, et al.. (2020). Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. British Journal of Cancer. 122(10). 1453–1460. 23 indexed citations

Rabaglio, Manuela, Zhuoxin Sun, Rudolf Maibach, et al.. (2020). Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. Breast Cancer Research and Treatment. 185(3). 697–707. 8 indexed citations

Finn, Richard S., John Crown, Johannes Ettl, et al.. (2016). Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Research. 18(1). 67–67. 136 indexed citations

Martín, Miguel, Moshe Inbar, Eva Carrasco, et al.. (2015). Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006). Journal of Clinical Oncology. 1 indexed citations

Finn, Richard S., John Crown, István Láng, et al.. (2014). The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. The Lancet Oncology. 16(1). 25–35. 1412 indexed citations breakdown →

10.

Moy, Beverly, Patrick Neven, Fabienne Lebrun, et al.. (2014). Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer. The Oncologist. 19(4). 348–349. 25 indexed citations

11.

Finn, Richard S., John Crown, Katalin Boér, et al.. (2012). 100O Results of A Randomized Phase 2 Study of Pd 0332991, A Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, In Combination with Letrozole vs Letrozole Alone For First-Line Treatment of ER + /Her2- Advanced Breast Cancer (Bc). Annals of Oncology. 23. ii43–ii43. 30 indexed citations

12.

Cutsem, Eric Van, István Láng, G D’Haens, et al.. (2008). The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri. Annals of Oncology. 19. 17–17. 11 indexed citations

13.

Láng, István & Erika Hitre. (2006). [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer].. PubMed. 50(4). 293–302. 2 indexed citations

14.

Láng, István. (2002). [Possibilities and results with Herceptin-Taxol combination in the treatment of breast cancer].. PubMed. 46(2). 195–6. 1 indexed citations

15.

Fehér, János, et al.. (1989). Liver cell protection in toxic liver lesion.. PubMed. 73(2-3). 285–91. 7 indexed citations

16.

Deák, György, et al.. (1989). Depressed monocyte production of interleukin‐1 and tumor necrosis factor‐alpha in patients with alcoholic liver cirrhosis. Liver International. 9(5). 302–306. 23 indexed citations

17.

Láng, István, et al.. (1985). The biopotential of Hungary - present and future.. International Agrophysics. 1(1). 5–22. 1 indexed citations

18.

Láng, István. (1978). Hungary's Lake Balaton: a program to solve its problems.. AMBIO. 7(4). 164–168. 2 indexed citations

19.

Láng, István, M. Benczúr, Marta Alonso de la Varga, P Gergely, & G Petrányi. (1977). Antibody dependent and spontaneous lymphocyte mediated cytotoxicity in normal subjects, patients with SLE, and malignancies.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 34(3). 123–7. 6 indexed citations

20.

Láng, István, B. Fekete, Krisztina Pálóczi, et al.. (1977). Antibody-dependent cellular cytotoxicity in systemic lupus erythematosus.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 34(4). 259–65.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact